TABLE 1.
Baseline characteristics of patients
| KTR (n = 26) | DP (n = 11) | |
|---|---|---|
| M/F ratio | 25/16 = 1.6 | 9/5 = 1.8 |
| Age, mean ± SD, y | 58.6 ± 14.3 | 61.4 ± 17.7 |
| eGFR, mean ± SD, mL/min/1.73 m2 | 41.9 ± 9.2 | – |
| Heart failure | 6 (23) | 7 (63.6) |
| Diabetes | 6 (23) | 5 (45.4) |
| Cancer | 1 (3.8) | 0 (0) |
| Respiratory disease | 3 (11.5) | 1 (9) |
| Hypertension | 20 (76.9) | 8 (72.7) |
| BMI, kg/m2, median (IQR) | 27 (22–41) | 26 (23–38) |
| PD/HD, n | – | 2/9 |
| Time from KT, mean ± SD, y | 6.3 ± 5.4 | – |
| <1 y, n (%) | 4 (15.4) | – |
| DD, n (%) | 22 (84.6) | – |
| LKD, n (%) | 4 (15.4) | – |
| Induction at KTR, n (%) | ||
| ATG | 10 (38.5) | – |
| BAS | 16 (61.5) | – |
| IT at time of infection, n (%) | ||
| CNI + MMF | 20 (76.9) | – |
| CNI + AZA | 1 (3.8) | – |
| CNI + mTor-I | 1 (3.8) | – |
| Bela + MMF | 2 (7.7) | – |
| Bela monotherapy | 1 (3.8) | – |
| Steroids | 14 (53.8) | – |
| Hospitalization for COVID-19 infection, n (%) | 19 (73.1) | 9 (81.8) |
| ICU, n (%) | 3 (11.5) | 2 (18.2) |
| SARS-CoV-2 pneumonia, n (%) | 16 (61.5) | 6 (54.5) |
| % of pulmonary involvement, n | ||
| <25% | 8 | 4 |
| ≥25% | 8 | 2 |
ATG, antithymocyte globulins; AZA, azathioprine; BAS, basiliximab; bela, belatacept; BMI, body mass index; CNI, calcineurin inhibitor; COVID-19, coronavirus disease 2019; DD, deceased donor; DP, dialyzed patients; eGFR, estimated glomerular filtration rate; F, female; HD, hemodialysis; IT, immunosuppressive therapy; ICU, intensive care unit; IQR, interquartile range; KTR, kidney transplant recipient; LKD, living kidney donor; M, male; MMF, mycophenolate mofetil; mTor, mammalian target of rapamycin; mTor-I, mTor inhibitor; PD, peritoneal dialysis; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.